Cytotoxic pathways activated by multifunctional thiosemicarbazones targeting sigma-2 receptors in breast and lung carcinoma cells.
Adenocarcinoma breast tumor
Adenocarcinoma lung tumor
Caspase 3/7/9
ER and mitochondrial stress
Sigma receptor
Thiosemicarbazones
Journal
Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
22
06
2023
accepted:
13
09
2023
revised:
12
09
2023
medline:
22
11
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
ppublish
Résumé
Multifunctional thiosemicarbazones (TSCs) able to bind sigma receptors and chelate metals are considered as a promising avenue for the treatment of pancreatic cancer due to the encouraging results obtained on in vitro and in vivo models. Here, we assessed the biochemical mechanism of these TSCs also on lung (A549) and breast (MCF7) cancer cells. The density of sigma-2 receptors in normal (BEAS-2B and MCF10A) and in lung and breast (A549 and MCF7) cancer cells was evaluated by flow cytometry. In these cells, cytotoxicity (MTT assay) and activation of ER- and mitochondria-dependent cell death pathways (by spectrofluorimetric assays to measure Caspases 3/7/9; qRT-PCR detection of GRP78, ATF6, IRE1, PERK; MitoSOX, DCFDA-AM and JC-1 staining), induced by the TSCs FA4, MLP44, PS3 and ACThio1, were evaluated. FA4 and PS3 exerted more potent cytotoxicity than MLP44 and ACThio1 in all cancer cell lines, where the density of sigma-2 receptors was higher than in normal cells. Remarkably, FA4 promoted ER- and mitochondria-dependent cell death pathways in both cell models, whereas the other TSCs had variable, cell-dependent effects on the activation of the two proapoptotic pathways. Our data suggest that FA4 is a promising compound that deserves to be further studied for lung and breast cancer treatment. However, the other multifunctional TSCs also hold promise for the development of therapies towards a personalized medicine approach. Indeed, the presence of the sigma-2 receptor-targeting moiety would lead to a more specific tumor delivery embracing the characteristics of individual tumor types.
Sections du résumé
BACKGROUND
BACKGROUND
Multifunctional thiosemicarbazones (TSCs) able to bind sigma receptors and chelate metals are considered as a promising avenue for the treatment of pancreatic cancer due to the encouraging results obtained on in vitro and in vivo models. Here, we assessed the biochemical mechanism of these TSCs also on lung (A549) and breast (MCF7) cancer cells.
METHODS
METHODS
The density of sigma-2 receptors in normal (BEAS-2B and MCF10A) and in lung and breast (A549 and MCF7) cancer cells was evaluated by flow cytometry. In these cells, cytotoxicity (MTT assay) and activation of ER- and mitochondria-dependent cell death pathways (by spectrofluorimetric assays to measure Caspases 3/7/9; qRT-PCR detection of GRP78, ATF6, IRE1, PERK; MitoSOX, DCFDA-AM and JC-1 staining), induced by the TSCs FA4, MLP44, PS3 and ACThio1, were evaluated.
RESULTS
RESULTS
FA4 and PS3 exerted more potent cytotoxicity than MLP44 and ACThio1 in all cancer cell lines, where the density of sigma-2 receptors was higher than in normal cells. Remarkably, FA4 promoted ER- and mitochondria-dependent cell death pathways in both cell models, whereas the other TSCs had variable, cell-dependent effects on the activation of the two proapoptotic pathways.
CONCLUSIONS
CONCLUSIONS
Our data suggest that FA4 is a promising compound that deserves to be further studied for lung and breast cancer treatment. However, the other multifunctional TSCs also hold promise for the development of therapies towards a personalized medicine approach. Indeed, the presence of the sigma-2 receptor-targeting moiety would lead to a more specific tumor delivery embracing the characteristics of individual tumor types.
Identifiants
pubmed: 37796435
doi: 10.1007/s43440-023-00531-y
pii: 10.1007/s43440-023-00531-y
pmc: PMC10661773
doi:
Substances chimiques
sigma-2 receptor
0
Receptors, sigma
0
Thiosemicarbazones
0
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1588-1596Subventions
Organisme : Compagnia di San Paolo
ID : Funding 2021
Informations de copyright
© 2023. The Author(s).
Références
Int J Mol Sci. 2020 May 08;21(9):
pubmed: 32397184
Eur J Med Chem. 2018 Jan 20;144:359-371
pubmed: 29287249
Cancer Lett. 2015 May 1;360(2):219-26
pubmed: 25681670
Cell Death Dis. 2016 Jul 21;7:e2307
pubmed: 27441659
Biochim Biophys Acta. 2011 May;1813(5):1003-13
pubmed: 21146562
Cancers (Basel). 2020 Jan 21;12(2):
pubmed: 31973006
BMC Cancer. 2017 Jan 13;17(1):51
pubmed: 28086830
Cell Oncol (Dordr). 2021 Dec;44(6):1307-1323
pubmed: 34586588
Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):106-13
pubmed: 15322732
Molecules. 2021 Jun 19;26(12):
pubmed: 34205334
Eur J Med Chem. 2019 Jul 15;174:226-235
pubmed: 31042618
Cell Death Dis. 2018 Feb 14;9(2):245
pubmed: 29445138
J Exp Clin Cancer Res. 2012 May 02;31:41
pubmed: 22551149
Mol Oncol. 2014 Jul;8(5):956-67
pubmed: 24731702
Sci Rep. 2020 Jun 18;10(1):9928
pubmed: 32555254
Cancer Res. 2005 Oct 1;65(19):8975-83
pubmed: 16204071
Biochim Biophys Acta Mol Cell Res. 2020 Dec;1867(12):118824
pubmed: 32828758
Front Pharmacol. 2018 Jul 10;9:711
pubmed: 30042674
Chembiochem. 2015 May 4;16(7):1078-83
pubmed: 25757101
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Cell Death Dis. 2013 Oct 03;4:e818
pubmed: 24091661
ChemMedChem. 2013 Dec;8(12):2026-35
pubmed: 24106081
Eur J Pharmacol. 2021 Sep 5;906:174263
pubmed: 34144027
Surgery. 2012 Sep;152(3 Suppl 1):S152-6
pubmed: 22763259
Biochim Biophys Acta Gen Subj. 2022 Aug;1866(8):130152
pubmed: 35436509